A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study of SHR-A2102 for Injection Versus Investigator-selected Therapy in Locally Advanced or Metastatic Urothelial Carcinoma Previously Treated With Platinum-Containing Chemotherapy and PD-(L)1 Inhibitors and With or Without ADC
Latest Information Update: 10 Mar 2025
At a glance
- Drugs SHR A2102 (Primary) ; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Carcinoma; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Hengrui Pharmaceutical
Most Recent Events
- 05 Mar 2025 Status changed from not yet recruiting to recruiting.
- 20 Dec 2024 New trial record